Why Proteomics Matters (in cancer research) 

Proteins can directly reflect functional cellular states and clinically relevant endpoints. Protein abundance variations can only 40–60% of the time be explained by changes of the transcript level alone, revealing an additional layer of critical regulatory complexity. Many proteins are already FDA-approved biomarkers for a variety of applications (e.g., CRP, HER2, PD-L1) and serve as targets for over 90% of approved drugs. This makes proteomics a uniquely powerful approach for uncovering disease mechanisms and identifying actionable biomarkers that guide modern cancer therapies.

Our Technology 

We primarily leverage state-of-the-art mass spectrometry (MS) as our platform for proteomics analysis. Modern MS workflows can quantify more than 9,000 proteins per sample with exceptional sensitivity, dynamic range and speed (e.g. 40–120 samples per day). This approach provides deep coverage and rapid analysis times making it ideal for clinical and translational research applications.

Our Team

The staff is composed of a dynamic group with different skill sets, bringing together technical specialists, bioinformaticians and scientists with decades of expertise. This multidisciplinary approach ensures we deliver comprehensive solutions — from cutting-edge instrumentation and data analysis to innovative research strategies — tailored to the needs of our collaborators

Applications

We routinely analyze proteins from diverse biological matrices, including cells, conditioned media, plasma/serum and tissue (fresh frozen or FFPE) samples. Our services encompass a wide range of advanced proteomics applications, such as global proteome profiling, targeted quantitation and post-translational modification analysis (e.g., phosphoproteomics).